Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of Intravenous Difelikefalin in Hemodialysis Adolescents with Moderate-to-Severe Pruritus
ChiCTR2500109843Phase 2Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of difelikefalin in chronic kidney disease (CKD), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Safety of difelikefalin 0.5 µg/kg in hemodialysis adolescents with moderate-to-severe pruritus. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500109843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109843.